| Code | CSB-RA004937MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar of dapirolizumab pegol, targeting CD40LG (CD40 ligand; CD40L, also known as CD154)—a key T-cell costimulatory molecule in the CD40–CD40L axis that coordinates adaptive immune activation. CD40L signaling helps drive B-cell activation, germinal center responses, immunoglobulin class switching, and affinity maturation, and it also “licenses” antigen-presenting cells to support T-cell priming. Dysregulated CD40–CD40L signaling has been implicated in autoimmune pathology, including mechanisms relevant to systemic lupus erythematosus (SLE) such as amplified B-cell responses and autoantibody production.
Dapirolizumab pegol (CDP7657) is an Fc-free, PEG-conjugated anti-CD40L Fab’ designed to inhibit CD40L signaling and modulate immune activation pathways. This biosimilar provides the antibody reagent for studying CD40L target engagement, CD40-dependent immune synapse biology, and downstream functional readouts (e.g., B-cell activation programs, APC activation, and interferon-associated immune pathways) in controlled experimental systems—supporting mechanism-of-action research and assay development around CD40–CD40L pathway modulation.
There are currently no reviews for this product.